Determining the Utility of a Behavioral Intervention in Chronic Migraine
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Mayo Clinic
- Study ID
- NCT05415020
- Status
- Recruiting
Conditions
- Chronic Migraine
- Headache
- Headache Disorders
- Lifestyle Factors
- Migraine
- Migraine Disorders
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Lifestyle Behavior Protocol — BEHAVIORALVirtual training on building a skillset to improve lifestyle behavior that reduces migraine attacks
- Sham Behavior Protocol — BEHAVIORALVirtual training on the disease of migraine and how migraine can progress to chronic migraine.
Study Details
This proposal will involve a pilot study to evaluate the feasibility, acceptability, and outcomes of a lifestyle behavior protocol in managing chronic migraine. Additionally, the proposal will investigate biomolecules that are uniquely involved in chronic migraine patients who respond to the protocol. Successful completion of this proposal will inform the design of a future full-scale behavioral clinical trial to control chronic migraine.
Key Dates
- Start date
- Jun 29, 2022
- Status verified
- Jun 2026
- Primary completion
- May 31, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Virtual Therapy Group
- Sham Comparator: Attention Placebo Group
Primary Outcome Measure
Number of Interested Participants that are Enrolled [ Time Frame: 12 weeks ]
Central Contacts
- Dr. Yohannes W. Woldeamanuel, MD650-933-3560
- Migraine Study480-342-1385
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 |
Find similar trials in Phoenix, AZ
By condition
By specialty
By research site
Related Studies
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)PHASE3 · Recruiting · AbbVie · Huntsville, Alabama
- Responding With Evidence and Access for Childhood HeadachesRecruiting · Children's Hospital Medical Center, Cincinnati · Birmingham, Alabama
- Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive MedicationsPHASE4 · Recruiting · Mayo Clinic · Phoenix, Arizona
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigrainePHASE3 · Recruiting · AbbVie · Birmingham, Alabama